i agree patty. But markets look at future earnings, i think the share price could be fair value of some 400 million before cvac being approved for commercialisation and even before phase 111 results. DNDN obviously is ahead off prr in terms of trials, but they have a market cap of approx 3 billion. i see a premium for prr still to come based on possible commercialisation of a product similar to one that is receiving massive attention in america, and based on this, there could be excitement still with prr. GOODLUCK :)
i agree patty. But markets look at future earnings, i think the...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.005(1.27%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 41.0¢ | 38.5¢ | $1.351M | 3.389M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16911 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 154170 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |